刺五加脑灵合剂在神经衰弱患者临床治疗中的应用效果  

Application Effect of Ciwujia Naoling Mixture in the Clinical Treatment of Neurasthenia Patients

作　　者：边凤明 BIAN Feng-Ming(Department of Neurology,Harbin No.5 Hospital,Harbin 150036,China)

机构地区：[1]哈尔滨市第五医院神经内科,哈尔滨150036

出　　处：《中国药物经济学》2025年第3期43-46,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨刺五加脑灵合剂在神经衰弱患者临床治疗中的应用效果。方法选取2022年1月至2023年3月于哈尔滨市第五医院治疗的120例神经衰弱患者,随机分为对照组(60例)和观察组(60例)。对照组给予西药帕罗西汀片治疗,观察组在对照组用药基础上加用刺五加脑灵合剂治疗。比较两组临床疗效、精神症状评分、睡眠质量评分、不良情绪以及不良反应发生率。结果观察组治疗总有效率明显高于对照组,治疗后症状自评量表(SCL-90)评分、匹茨堡睡眠质量指数(PSQI)评分、汉密尔顿焦虑量表(HAMA)评分、汉密尔顿抑郁量表(HAMD)评分、不良反应发生率均显著低于对照组,差异有统计学意义(P<0.05)。结论刺五加脑灵合剂在神经衰弱患者临床治疗中的应用效果显著,可有效改善患者临床症状和睡眠质量,减轻不良情绪,且用药安全性良好。Objective To explore the application effect of Ciwujia Naoling mixture in the clinical treatment of neurasthenia patients.Methods 120 patients with neurasthenia treated in The Fifth Hospital Of Harbin City from January 2022 to March 2023were selected as research objects,and were divided into control group(60 cases)and observation group(60 cases)according to the principle of numerical parity.The control group was treated with paroxetine tablets,and the observation group was treated with Ciwujia Naoling mixture on the basis of the control group.The clinical efficacy,psychiatric symptom score,sleep quality score,bad emotion and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was significantly higher than that of the control group,and the score of SCL-90,Pittsburgh Sleep Quality Index(PSQI),Hamilton Anxiety Scale(HAMA),Hamilton Depression Scale(HAMD)and incidence of adverse reactions were significantly lower than those of the control group,the difference was statistically significant(P<0.05).Conclusion The application of Ciwujia Naoling mixture in the clinical treatment of neurasthenia patients is remarkable,can effectively improve the clinical symptoms and sleep quality of patients,reduce bad emotions,and the drug safety is good.

关 键 词：刺五加脑灵合剂 神经衰弱 睡眠质量 不良情绪 不良反应 

分 类 号：R749.7[医药卫生—神经病学与精神病学] R971[医药卫生—临床医学]